NEW HOPE FOR SERIOUS INFECTIONS

Cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives. Our drug candidates include biafungin and topifungin, long-acting echinocandin antifungals, and C-001, developed using our Cloudbreak™ immunotherapy platform.

Cidara seeks to improve patients’ lives through the discovery, development and commercialization of novel, best-in-class, anti-infectives. Our initial portfolio is comprised of proprietary product candidates for the treatment of serious fungal infections.

Biafungin

Our lead product candidate, biafungin, is a novel molecule in the echinocandin class of antifungals. We are initially developing biafungin for the treatment of systemic Candida infections. We intend to complete IND-enabling studies and start a Phase I clinical trial in 2015.

Topifungin

We are developing topifungin for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC). Topifungin has demonstrated potent fungicidal activity against Candida species in vitro and has unique physical properties allowing its formulation as a topical agent.

Cloudbreak™

Cloudbreak is a proprietary immunotherapy platform being used to create compounds that direct a patient’s immune cells to attack pathogens that cause infectious disease. Our first candidate, C-001, is being developed for the treatment of invasive aspergillosis.

Opportunity

Fungal infections pose significant medical challenges in both the hospital and outpatient settings. These infections typically afflict immunocompromised persons including patients undergoing organ or bone marrow transplantation, chemotherapy, or patients with AIDS.

GET IMPORTANT NEWS AND UPDATES BY EMAIL